title: Expression of survivin does not predict survival in patients with transitional cell carcinoma of the upper urinary tract.
abstract: The members of the IAP (inhibitors of apoptosis) family, which includes survivin, have recently emerged as modulators of an evolutionarily conserved step in apoptosis. Survivin is present during embryonic and fetal development, but it is downregulated in normal adult tissues. However, it becomes re-expressed in a variety of cancers. We investigated the prognostic importance of the expression of survivin in transitional cell carcinoma of the upper urinary tract (TCC-UUT). In 126 cases of TCC-UUT, we examined its expression (using immunohistochemistry), and also its relationship with the expressions of bcl-2 oncoprotein, p53 oncoprotein, and proliferating cell nuclear antigen (PCNA) immunoreactivity, clinicopathologic parameters, and clinical outcome. A positive expression of survivin was recognized in 12.7% of samples, a granular pattern being apparent within the cytoplasm of tumor cells. Survivin expression did not correlate with clinicopathologic findings, bcl-2 oncoprotein expression, p53 oncoprotein expression, PCNA index, or prognosis. In the normal urothelium, its expression was not detected. In conclusion, the expression of survivin does not predict prognosis in TCC-UUT.
authors.affiliation: Division of Environmental Medicine, National Defense Medical College Research Institute, Tokorozawa 359-8513, Japan. nknsknak@res.ndmc.ac.jp
authors.forename: Kuniaki
authors.initials: K
authors.lastname: Nakanishi
authors.forename: Susumu
authors.initials: S
authors.lastname: Tominaga
authors.forename: Sadayuki
authors.initials: S
authors.lastname: Hiroi
authors.forename: Toshiaki
authors.initials: T
authors.lastname: Kawai
authors.forename: Shinsuke
authors.initials: S
authors.lastname: Aida
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Kasamatsu
authors.forename: Takashi
authors.initials: T
authors.lastname: Aurues
authors.forename: Takuya
authors.initials: T
authors.lastname: Hayashi
authors.forename: Tomosumi
authors.initials: T
authors.lastname: Ikeda
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D002295:Carcinoma, Transitional Cell / Q000378:metabolism* / Q000401:mortality / Q000556:secondary; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D051034:Inhibitor of Apoptosis Proteins; D007680:Kidney Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D008297:Male; D008869:Microtubule-Associated Proteins / Q000378:metabolism*; D008875:Middle Aged; D009363:Neoplasm Proteins; D009378:Neoplasms, Multiple Primary; D011379:Prognosis; D018809:Proliferating Cell Nuclear Antigen / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D015996:Survival Rate; D000077022:Survivin; D016159:Tumor Suppressor Protein p53 / Q000378:metabolism; D014516:Ureteral Neoplasms / Q000378:metabolism* / Q000401:mortality / Q000473:pathology; D001749:Urinary Bladder Neoplasms / Q000473:pathology; D019459:Urothelium / Q000166:cytology / Q000378:metabolism / Q000473:pathology
chemical_list: C107489:BIRC5 protein, human; D014408:Biomarkers, Tumor; D051034:Inhibitor of Apoptosis Proteins; D008869:Microtubule-Associated Proteins; D009363:Neoplasm Proteins; D018809:Proliferating Cell Nuclear Antigen; D019253:Proto-Oncogene Proteins c-bcl-2; D000077022:Survivin; D016159:Tumor Suppressor Protein p53